Financial Performance - The group's revenue for the year ended December 31, 2025, was RMB 18,112.6 million, a decrease of 12.7% compared to the previous year[2]. - The group's gross profit for the same period was RMB 11,775.4 million, down 14.5% year-over-year[2]. - The net profit for the year was RMB 2,093.8 million, representing a significant decline of 42.7% from the previous year[2]. - Basic and diluted earnings per share were both RMB 0.21, compared to RMB 0.39 in 2024[2]. - The company reported a total comprehensive income of RMB 1,918.5 million for the year, down from RMB 3,570.1 million in 2024[5]. - The pre-tax profit for 2025 is RMB 6,337,185 thousand, down from RMB 6,983,747 thousand in 2024, indicating a decrease of about 9.3%[35]. - The company's net profit for the year dropped by 42.7% from RMB 3,654.1 million in 2024 to RMB 2,093.8 million in 2025[71]. - The pre-tax profit decreased by 39.6% from RMB 5,549.7 million in 2024 to RMB 3,352.2 million in 2025[69]. - The infant formula product revenue decreased by 16.8% from RMB 19,061.6 million in 2024 to RMB 15,868.3 million in 2025, representing 87.6% of total revenue[59]. Assets and Liabilities - Total assets as of December 31, 2025, were RMB 27,289.4 million, a decrease from RMB 29,134.7 million in 2024[6]. - Current assets decreased to RMB 20,257.2 million from RMB 22,248.6 million in the previous year[6]. - The total liabilities increased slightly to RMB 6,749.3 million from RMB 6,591.0 million in 2024[6]. - Non-current liabilities decreased from RMB 1,727,291 thousand in 2024 to RMB 1,167,941 thousand in 2025, a reduction of approximately 32.3%[7]. - Net asset value decreased from RMB 27,407,385 thousand in 2024 to RMB 26,121,488 thousand in 2025, a decline of about 4.7%[7]. - Total equity decreased from RMB 27,407,385 thousand in 2024 to RMB 26,121,488 thousand in 2025, representing a decrease of approximately 4.7%[7]. - The total liabilities for the year ending December 31, 2025, are RMB 7,917,258, a decrease from RMB 8,318,321 in 2024, representing a decline of approximately 4.8%[22][24]. Cash Flow and Capital Expenditure - The net cash flow from operating activities for the group in 2025 was RMB 2,213.8 million, compared to RMB 4,179.3 million in 2024[78]. - The net cash flow from investing activities in 2025 was RMB 9.6 million, a significant decrease from RMB 1,316.8 million in 2024[78]. - The group's total capital expenditure for the year ended December 31, 2025, was approximately RMB 1,519.8 million, mainly due to property, plant, and equipment investments[81]. Dividends - The board proposed a final dividend of HKD 0.1290 per share, down from HKD 0.1632 per share in 2024[2]. - The interim dividend declared per ordinary share is HKD 0.1209 for 2025, down from HKD 0.1632 in 2024, equivalent to about RMB 1.0 billion compared to RMB 1.35 billion in the previous year[38]. - The company proposed a final dividend of HKD 0.1290 per share for the year ending December 31, 2025, totaling approximately HKD 1,135,997,019 (equivalent to about RMB 1,000,000,000) pending shareholder approval[96]. - The dividend policy aims to distribute no less than 30% of the net profit for each fiscal year, subject to future investment plans[97]. Market and Industry Trends - China's birth rate has declined from 8.52‰ in 2020 to 5.63‰ in 2025, resulting in a decrease in newborns to approximately 7.9 million[45]. - The number of children aged 0-3 years is projected to decrease from approximately 41.9 million in 2020 to about 26.5 million in 2025, impacting the infant formula market[45]. - The average disposable income in China is expected to reach RMB 43,377 in 2025, with a compound annual growth rate of 6.1% from 2020 to 2025, enhancing demand for premium infant formula products[45]. - The Chinese government aims to maintain a 60% self-sufficiency level for domestically produced infant formula, encouraging the use of fresh milk in production[46]. - New national safety standards for infant formula were implemented in February 2023, setting stricter regulations on protein, carbohydrates, and micronutrients, benefiting leading companies in the industry[46]. - The government has introduced supportive measures for the three-child policy to counteract declining birth rates, including increased maternity benefits and healthcare insurance[46]. Company Operations and Strategy - The company was established in October 2012 and is engaged in the production and sale of dairy products and nutritional supplements[8]. - The company was listed on the Hong Kong Stock Exchange on November 13, 2019[9]. - The group has established 11 production facilities with a designed annual capacity of over 438,000 tons as of December 31, 2025[52]. - The group aims to optimize its production arrangements to enhance capacity and efficiency[52]. - The group offers a diversified product portfolio to meet a wide range of customer needs, including ultra-high-end and high-end categories[49]. - The group has implemented innovative online and offline marketing strategies to strengthen brand recognition in the Chinese infant formula market[53]. - The company has established an audit committee consisting of three members to oversee financial reporting and risk management[94]. - The audit committee reviewed the financial statements for the year ending December 31, 2025, ensuring compliance with accounting principles[94]. - The company maintains a commitment to corporate governance, adhering to the guidelines set forth by the Hong Kong Stock Exchange[89]. Share Buyback and Securities - The company repurchased a total of 259,587,000 shares during the reporting period, with a total cost of HKD 1,100,059,040[91]. - The highest price paid per share during the buyback was HKD 4.70, while the lowest was HKD 4.02[91]. - The board believes that the share buyback reflects confidence in the company's market position and long-term growth prospects[92]. - The company has not engaged in any other purchases or sales of its listed securities during the reporting period[91]. - The company will apply the remaining unutilized net proceeds from the global offering as outlined in the prospectus[93].

Financial Performance - Total revenue increased from RMB 764.5 million in the year ended December 31, 2024, to RMB 906.972 million in the reporting period, representing an 18.6% growth[11]. - Gross profit rose to RMB 223.190 million, up 43.0% from RMB 156.051 million in the previous year, with a gross margin improvement to 24.6%[4]. - Operating profit increased by 54.6% to RMB 84.470 million, compared to RMB 54.641 million in the prior year[4]. - Profit before tax grew by 36.7% to RMB 96.053 million, up from RMB 70.243 million in the previous year[4]. - Net profit for the year reached RMB 71.841 million, a significant increase of 62.1% from RMB 44.317 million in the previous year[4]. - Adjusted net profit decreased by 18.4% to RMB 81.629 million, compared to RMB 100.046 million in the previous year[4]. Revenue Breakdown - Revenue from artist management increased by 12.4% to RMB 748.51 million, accounting for 82.5% of total revenue[14]. - Revenue from music IP production and operation grew by 30.7% to RMB 55.19 million, representing 6.1% of total revenue[14]. - IP operations revenue increased by 16.6% from RMB 56.7 million in 2024 to RMB 66.1 million in 2025, primarily driven by growth in artist-related merchandise[21]. - The潮玩 (trendy toys) business generated revenue of RMB 37.1 million during the reporting period, with a gross profit of RMB 16.7 million and a gross margin of 45.0%[25]. Artist Management and IP Development - The company has 64 signed artists and 55 trainees in its training program as of December 31, 2025[6]. - The company plans to continue developing and incubating more toy IPs to meet changing market demands, contributing to sustainable growth in the toy business[10]. - The company's artist-related merchandise and concerts continued to provide stable contributions to revenue, enhancing brand visibility and audience engagement[9]. - The company has established a music IP library containing over 1,240 original and licensed music works[18]. - The company plans to continue developing its music IP business to address the rapidly growing Chinese digital music market[19]. Cost and Expenses - Total operating costs rose by 12.4% from RMB 608.5 million to RMB 683.8 million, primarily due to increased costs in artist management and toy business operations[35]. - Sales and marketing expenses include employee benefits, marketing promotions, and travel costs, reflecting the company's investment in artist promotion and brand visibility[41]. - Employee benefits expenditure increased by 10.4% from RMB 28,187 thousand in 2024 to RMB 31,113 thousand in 2025, representing 50.6% of total expenses[43]. - Total sales and marketing expenses rose by 4.2% from RMB 59.0 million in 2024 to RMB 61.5 million in 2025, primarily due to increased employee benefits expenditure[44]. Financial Position - The company's cash and cash equivalents decreased from RMB 386.1 million as of December 31, 2024, to RMB 323.2 million as of December 31, 2025[71]. - Trade receivables increased by 49.9% from RMB 71.9 million as of December 31, 2024, to RMB 107.8 million as of December 31, 2025, primarily due to increased revenue from artist management[65]. - Trade payables increased by 20.1% from RMB 202.7 million as of December 31, 2024, to RMB 243.4 million as of December 31, 2025, due to increased business volume[68]. - The fair value of financial assets measured at fair value through profit or loss increased by 5.8% from RMB 374.1 million as of December 31, 2024, to RMB 395.9 million as of December 31, 2025[64]. Shareholder Matters - The company did not recommend the payment of a final dividend for the years ended December 31, 2025, and 2024[118]. - The annual general meeting is scheduled for June 18, 2026, to discuss shareholder matters[132]. - The company will suspend share transfer registration from June 15, 2026, to June 18, 2026, to determine eligible shareholders for the annual general meeting[133]. - The company repurchased a total of 32,037,000 shares at a total cost of HKD 68,985,510 during the reporting period, demonstrating confidence in long-term growth prospects[128][129]. Corporate Governance and Structure - The company is a limited liability company registered in the Cayman Islands on June 10, 2021[137]. - The company operates primarily in China and South Korea, focusing on artist management and IP operations[96]. - The company’s governance is in accordance with the corporate governance code as per the listing rules[137]. - The company has adopted a share incentive plan on December 10, 2021, prior to its initial public offering[138].

Financial Performance - The company's revenue for the year ended December 31, 2025, was RMB 1,623,177,000, a decrease of 53.5% compared to RMB 3,488,094,000 in 2024[3]. - Gross profit for the same period was RMB 775,080,000, down 10.0% from RMB 861,672,000 in 2024[3]. - Operating loss increased to RMB (853,301,000), a rise of 126.9% from RMB (376,141,000) in the previous year[3]. - The adjusted net loss (non-IFRS measure) was RMB (182,129,000), up 56.9% from RMB (116,093,000) in 2024[3]. - The company reported a net loss of RMB 968.5 million for the reporting period, an increase of 97.1% year-on-year, primarily due to losses from divested subsidiaries and one-time provisions[17]. - The company recorded a net loss of approximately RMB 491.4 million for the fiscal year ending December 31, 2024, increasing by 97.1% to approximately RMB 968.5 million for the fiscal year ending December 31, 2025, primarily due to losses from the sale of subsidiaries[51]. - The company reported a basic loss per share of RMB 1.52 for the year ended December 31, 2025, compared to RMB 0.89 for 2024, based on a weighted average of 609,853,000 shares outstanding[114]. Revenue Breakdown - Revenue from in-hospital solutions was RMB 1,188.8 million, a decrease of 55.7% from RMB 2,683.3 million in the previous year[23]. - Revenue from outpatient solutions dropped by 46.0% from approximately RMB 804.8 million in 2024 to approximately RMB 434.4 million in 2025, primarily due to a strategic focus on AI-assisted pharmacy solutions and P2M solutions[39]. - Revenue from the P2M solution reached RMB 419.1 million, a significant increase of 46.6% compared to RMB 286.0 million in the previous year[21]. - The P2M solutions generated total revenue of RMB 504.5 million as of December 31, 2025, representing a substantial increase of 57.5% compared to December 31, 2024, achieving profitability[14]. - Revenue from subscription solutions (precision marketing) was RMB 253.9 million, a decrease of 9.9% from RMB 281.9 million in the previous year[23]. Operational Metrics - The average daily online effective prescription volume exceeded one million during the reporting period[7]. - The number of registered users on the company's pharmacy platform reached approximately 61.4 million, with online prescriptions totaling 371.6 million, reflecting a year-on-year growth of 40.5%[27]. - The company has connected over 18,000 hospitals, capturing 40% of the top 100 hospitals in China, with a penetration rate of over 30% in tertiary public hospitals[6]. - The company has installed its AI-driven pharmacy platform in 275,613 pharmacies, representing approximately 40% of the total pharmacies in China[7]. - The number of pharmacies using the AI-driven pharmacy platform increased by 13.6% to 275,613 in 2025[31]. Cost and Expenses - The total cost of goods sold was RMB 754,616,000 in 2025, significantly lower than RMB 2,565,680,000 in 2024, representing a decrease of approximately 70.7%[109]. - Sales cost decreased by 67.7% to approximately RMB 848.1 million in 2025, outpacing the revenue decline due to a shift towards higher-margin solutions[40]. - Personnel-related costs for the year ending December 31, 2025, amounted to approximately RMB 786.5 million, a decrease from RMB 842.6 million for the year ending December 31, 2024[69]. - The company's employee compensation expenses decreased to RMB 290,697,000 in 2025 from RMB 355,251,000 in 2024, a decline of approximately 18.1%[107]. Cash Flow and Liquidity - The company achieved a net cash inflow from operating activities of RMB 66.8 million in 2025, compared to a net cash outflow of RMB 148.4 million in the same period of 2024, indicating a necessary transformation[13]. - Cash and cash equivalents as of December 31, 2025, were approximately RMB 267.6 million, down from RMB 304.8 million as of December 31, 2024[56]. - The company's debt-to-asset ratio increased to 51.1% as of December 31, 2025, from 42.1% as of December 31, 2024, primarily due to a faster decline in total assets compared to total liabilities[63]. Strategic Focus and Future Plans - The company is focusing on a P2M strategy to achieve stable cash flow and profitability in the short term, with a long-term goal of monetizing data assets[13]. - The company plans to continue investing in product and technology innovation, focusing on medical AI models to strengthen its market position[36]. - The company aims to enhance the healthcare ecosystem's efficiency through technology and continues to build digital infrastructure for chronic disease management[9]. - The company has received sales approval for an important P2M pipeline product, which is expected to enhance long-term market expansion and profitability[15]. Corporate Governance and Compliance - The audit committee has reviewed the accounting policies and consolidated financial information for the year ending December 31, 2025[75]. - There were no significant lawsuits or arbitrations involving the company during the reporting period[78]. - The company did not engage in any significant investments or acquisitions during the year ended December 31, 2025[59][60]. Employee and Workforce - The company employed a total of 887 employees as of December 31, 2025, with the majority located in Hangzhou, Shanghai, and other offices in China[67]. - As of December 31, 2025, the total number of employees is 887, with 703 in sales and marketing, 66 in R&D, 47 in general and administration, and 71 in other functions[68].

Financial Performance - Total revenue for the year ended December 31, 2025, was HKD 36,144,000, a decrease of 44.5% from HKD 65,193,000 in 2024[2] - The company reported a loss attributable to shareholders of HKD 13,268,000 for 2025, compared to a profit of HKD 4,509,000 in 2024[3] - The net loss before tax for 2025 was HKD 9,552,000, a significant decline from a profit of HKD 6,593,000 in 2024[3] - The company reported a basic loss per share of HKD (13,268,000) for the year 2025, compared to a profit of HKD 4,509,000 in 2024[21] - The total comprehensive expenses amounted to HKD 14,865,000 in FY2025, significantly higher than the comprehensive income of HKD 4,884,000 in FY2024[49] Revenue Sources - Interest income from lending activities decreased to HKD 28,175,000 in 2025 from HKD 49,800,000 in 2024, representing a decline of 43.7%[8] - The lending business recorded a 46% decrease in revenue to HKD 28,175,000 in FY2025, down from HKD 51,944,000 in FY2024, and a 22% decrease in profit to HKD 35,643,000[41] - The securities brokerage business saw a 30% decrease in revenue to HKD 7,969,000 in FY2025, down from HKD 11,357,000 in FY2024, with profit dropping 81% to HKD 1,877,000[47] - The trading business generated no revenue in FY2025, consistent with FY2024, with a profit of HKD 8,122,000, down from HKD 10,181,000 in FY2024[40] Assets and Liabilities - Total assets decreased to HKD 2,206,779,000 in 2025 from HKD 2,231,737,000 in 2024, a reduction of 1.1%[4] - The total liabilities increased to HKD 206,857,000 in 2025 from HKD 38,927,000 in 2024, a rise of 431.5%[4] - The company’s equity decreased slightly to HKD 2,201,747,000 in 2025 from HKD 2,216,612,000 in 2024, a decrease of 0.7%[4] - The capital-to-debt ratio stood at approximately 10%, a significant increase from 2% in 2024, with total liabilities rising to HKD 211,889,000[52] Cash and Cash Equivalents - The company’s cash and cash equivalents increased to HKD 1,865,915,000 in 2025 from HKD 1,518,810,000 in 2024, an increase of 22.8%[4] - The company’s cash and bank balances increased from HKD 558,946,000 in 2024 to HKD 783,245,000 in 2025[15] Impairment and Provisions - The company recognized a net loss of HKD 5,626,000 in impairment losses for the year ending December 31, 2025[19] - The impairment provision for loans decreased by 49% to HKD 185,924,000 at year-end, down from HKD 365,835,000 in FY2024[43] - The impairment provision for receivables was HKD 6,212,000 in 2025, down from HKD 10,646,000 in 2024, indicating a decrease of about 41.5%[24] Strategic Acquisitions and Investments - The company completed the acquisition of a 26.3% stake in Citystate Savings Bank, Inc., marking a strategic entry into the Southeast Asian financial services sector[31] - A strategic acquisition of 51% of a target group engaged in digital payment services in Southeast Asia is planned, aimed at diversifying the financial services portfolio[54] - The company invested HKD 9,009,000 in a non-listed bank in the U.S. and HKD 14,799,000 in non-listed fixed-income securities during the fiscal year[36] Operational Strategy and Market Outlook - The company maintained a cautious operational strategy to navigate complex global conditions and geopolitical tensions[31] - The group maintains a cautious optimism regarding business prospects, benefiting from the ongoing recovery in Hong Kong and the vibrant economic activity in Southeast Asia[54] - The group aims to optimize synergies between financial services and business operations while exploring new investment opportunities in response to market changes[55]

Financial Performance - The company reported a loss attributable to shareholders of HKD 165,100,000 for the fiscal year ending December 31, 2025, compared to a loss of HKD 837,500,000 in the previous fiscal year[4]. - Total revenue for the year was HKD 2,530,067,000, a decrease from HKD 2,664,674,000 in the previous year, representing a decline of approximately 5%[5]. - Basic loss per share for the year was HKD 0.34, improved from HKD 1.75 in the previous year[5]. - The company recorded an operating profit of HKD 24,619,000, a significant recovery from an operating loss of HKD 286,081,000 in the prior year[5]. - The company experienced a total comprehensive loss of HKD 83,785,000 for the year, with a net loss attributable to owners of HKD 165,074,000[10]. - The reported segment loss for 2025 is HKD (39,866,000), compared to a loss of HKD (726,281,000) in 2024, indicating a significant improvement[23]. - The company reported a loss attributable to shareholders of HKD 165,074,000 for the year ended December 31, 2025, compared to a loss of HKD 837,464,000 in the previous fiscal year, representing a significant improvement[44]. Revenue Breakdown - Total revenue for the year ended December 31, 2025, was HKD 2,530,067,000, with HKD 2,467,196,000 from customer contracts and HKD 62,871,000 from rental income[20]. - The EMS segment generated revenue of HKD 2,467,200,000, down from HKD 2,603,000,000, with a segment profit of HKD 168,000,000, a decrease of 11.5% from HKD 189,800,000[46]. - The property holding segment reported revenue of HKD 62,900,000, slightly up from HKD 61,700,000, with a segment loss of HKD 207,800,000, significantly improved from a loss of HKD 916,100,000 in the previous year[47]. - Revenue from two major external customers accounted for approximately HKD 1,185,680,000 in 2025, representing about 10% of total revenue[24]. Assets and Equity - Total assets decreased to HKD 5,831,506,000 from HKD 6,158,836,000, reflecting a reduction of approximately 5.3%[7]. - Total equity attributable to shareholders decreased to HKD 3,406,104,000 from HKD 3,517,402,000, a decline of about 3.2%[8]. - The company’s total equity attributable to owners decreased from HKD 3,517,402,000 at the beginning of the year to HKD 3,406,104,000 by December 31, 2025[10]. - The net asset value attributable to joint ventures decreased to HKD 500,315,000 from HKD 604,695,000[35]. Cash Flow and Financing - The company’s cash and cash equivalents increased to HKD 793,683,000 from HKD 719,846,000, indicating a growth of approximately 10.2%[7]. - The company’s financing costs decreased to HKD 66,802,000 from HKD 73,022,000, a reduction of about 8.3%[5]. - The company reported a net financing cost of HKD (44,033,000) in 2025, compared to HKD (50,000,000) in 2024, indicating a reduction in financing costs[23]. - Total loans decreased to HKD 1,483,596,000 from HKD 1,618,928,000, with current liabilities increasing to HKD 894,746,000[40]. - As of December 31, 2025, the total bank credit of the group was HKD 2,627,200,000, a decrease from HKD 2,908,900,000 in 2024[48]. - The total bank loans amounted to HKD 1,483,600,000, down from HKD 1,618,900,000 in 2024[48]. Future Plans and Strategies - The company plans to focus on new product development and market expansion strategies in the upcoming fiscal year[4]. - The group anticipates a slight improvement in EMS business revenue in the first half of 2026 compared to the second half of 2025, driven by increased demand visibility and stable customer relationships[52]. - The group plans to expand capacity and upgrade technical capabilities in Vietnam to capture opportunities arising from supply chain diversification[53]. - The company plans to propose a final dividend of HKD 0.0200 per share for the year ending December 31, 2025, totaling approximately HKD 9,570,000[30]. - The company plans to pay a final dividend of HKD 0.0200 per share, down from HKD 0.0300 in the previous year[41]. Compliance and Governance - The group has adhered to the corporate governance code, with some deviations noted regarding the separation of roles between the chairman and CEO[56]. - The audit committee consists of three independent non-executive directors who reviewed the accounting principles and practices adopted by the group, discussing financial reporting matters for the year ending December 31, 2025[61]. - The auditor, PwC, confirmed that the figures in the preliminary performance announcement align with the draft consolidated financial statements for the year ending December 31, 2025, but did not provide any assurance or conclusion[62]. - The performance announcement is available on the company's website and the Hong Kong Stock Exchange website, with the annual report for 2025 to be published at an appropriate time[63].

Financial Performance - Biocytogen Pharmaceuticals reported its annual performance for the year ending December 31, 2025, with a comprehensive income statement included in the report [2]. - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion for the fiscal year, representing a 25% year-over-year growth [19]. - In 2025, the company achieved revenue of RMB1,378.8 million, representing a growth of approximately 40.6% compared to the previous year [29]. - The net profit for 2025 was RMB173.2 million, reflecting a significant increase of 416.4% year-over-year [31]. - The pre-clinical products and services business generated revenue of RMB1,046.4 million, up 58.0% from the previous year, with a gross profit margin of approximately 72.6% [50]. - Innovative animal model sales contributed RMB622.2 million in revenue, representing a 59.9% increase year-over-year, and maintained a gross profit margin of approximately 80.4% [50]. - The antibody discovery business recorded revenue of RMB332.4 million in 2025, a 4.6% increase from the previous year, with a gross profit margin of approximately 86.0% [51]. - The overseas business accounted for 68.2% of total revenue, generating RMB940.4 million, a 42.0% increase from the previous year, while domestic revenue reached RMB438.4 million, up approximately 37.8% [56]. Future Projections - The company provided guidance for the next fiscal year, projecting revenue growth of 30% to reach RMB 1.95 billion [19]. - The company provided an optimistic outlook, projecting a revenue growth of 20% for the next fiscal year, targeting RMB 1.8 billion [25]. - The company aims to enter into over 350 co-development/out-licensing/transfer development agreements by December 31, 2025, with more than 150 new deals signed in 2025, indicating rapid growth [73]. Research and Development - The company is investing RMB 200 million in R&D for new technologies, focusing on antibody-drug conjugates (ADCs) [19]. - R&D expenses reached RMB438.1 million in 2025, with an R&D expense ratio exceeding 30%, highlighting the company's commitment to technological leadership [57]. - The company has developed advanced gene editing platforms, including SUPCE, CRISPR/EGE, and ESC/HR, over more than a decade of dedicated research [150]. - The company has created approximately 5,000 unique gene-edited mouse/cell line projects for antibody discovery and disease models, which are essential for in-vivo efficacy evaluation [107]. - The company has developed and validated hundreds of syngeneic and xenogeneic tumor models to meet client scientific objectives [134]. Product Development - New product YH001 has entered the clinical trial phase, with expectations for market launch in Q3 2024 [19]. - YH001 and YH003 are core products, with YH001 showing good tolerability at doses not exceeding 6.0 mg/kg and promising anti-tumor activity in early trials [81][85]. - YH003 has completed Phase II MRCT clinical studies in patients with pancreatic duct adenocarcinoma (PDAC), demonstrating good safety and efficacy [86]. - The company plans to introduce innovative drug-ready molecules, including bis-antibodies, nano-antibodies, TCRm antibodies, and GPCR antibodies, to expand the richness of its antibody library [67][68]. Corporate Governance - The company has transitioned to a new governance structure following the completion of its A-share issuance and listing on the STAR Market on December 10, 2025, eliminating the Supervisory Committee [15][16]. - The company aims to enhance its corporate governance practices in line with the CG Code, ensuring compliance and transparency [19]. - The company has a dedicated investor relations contact, indicating a commitment to transparency and communication with stakeholders [15][16]. Market Expansion - Market expansion plans include entering the Southeast Asian market by the end of 2024, targeting a market share of 10% within the first year [19]. - The company is expanding its market presence in Southeast Asia, with plans to establish partnerships in three new countries by the end of 2025 [25]. - The company is actively exploring new animal models and cell testing models for various diseases, including cancer and autoimmune diseases, to support drug development [111]. Strategic Partnerships - A strategic partnership has been established with a leading CDMO to streamline production processes and reduce costs by 15% [19]. - The company has established stable cooperative relationships with all of the world's top 10 pharmaceutical companies, with overseas business accounting for 68.2% of total revenue [35][37]. - The company has entered into exclusive licensing agreements for YH001, YH002, and YH003 with Syncromune, which includes upfront payments and milestone payments [90]. Compliance and Quality Management - The company adheres to Good Clinical Practice (GCP) and Good Manufacturing Practices (GMP) to ensure high-quality clinical trials and manufacturing processes [21]. - The quality management department consists of about 60 employees, focusing on quality control based on ISO9001, GMP, and GLP systems, ensuring high standards in product development and manufacturing [198]. - The company emphasizes quality management in product design, R&D, manufacturing, testing, and transportation, actively involving management in quality policy formulation [200].

Revenue and Profitability - The group's revenue increased by approximately 36.4% to about HKD 1,066,000,000 for the year, compared to HKD 781,700,000 in the previous year[5] - The gross profit margin improved to approximately 4.1%, up from 1.0% in the previous year, driven by new customer acquisition and stable costs[5] - The group recorded a loss of approximately HKD 19,100,000, a reduction from a loss of HKD 46,200,000 in the previous year, attributed to growth in trade business and effective cost control measures[6] - Basic loss per share was HKD 1.47, compared to HKD 3.50 in the previous year, indicating improved financial performance[9] - The total comprehensive loss for the year was HKD 45,128,000, which includes a loss of HKD 18,957,000 for the year ended December 31, 2025[12] - The company reported a pre-tax loss of HKD 18,519,000 for the fiscal year 2025, compared to a pre-tax loss of HKD 46,208,000 in 2024, indicating an improvement in financial performance[30][31] - The company reported a pre-tax loss of HKD 18,957 for 2025, an improvement from a loss of HKD 45,090 in 2024[47] Assets and Liabilities - Non-current assets increased to HKD 159,126,000 from HKD 143,022,000, reflecting investments in property and equipment[10] - Trade and other receivables rose significantly to HKD 518,779,000 from HKD 169,518,000, indicating increased sales activity[10] - Current liabilities increased to HKD 957,978,000 from HKD 519,241,000, reflecting higher trade payables and borrowings[10] - Net current liabilities stood at HKD 417,322,000, compared to HKD 344,755,000 in the previous year, indicating a need for improved liquidity management[10] - The company's net liabilities increased to approximately HKD 520,034,000 in 2025 from HKD 494,149,000 in 2024, reflecting a rise of about 5.2%[15] - The company has a net current liability of approximately HKD 417,322,000 as of December 31, 2025, compared to HKD 344,755,000 in 2024, representing an increase of about 21.1%[15] - The total liabilities for the company were HKD 1,219,816,000, with segment liabilities accounting for HKD 712,300,000[32] Revenue Segmentation - The segment performance for the trading business in 2025 was HKD 8,415,000, while the warehousing business reported HKD 6,508,000, leading to a total segment performance of HKD 14,923,000[30] - Trade business revenue for 2025 reached HKD 1,030,924, an increase of 34.1% from HKD 769,032 in 2024[39] - The petrochemical storage business saw a revenue increase of approximately 175.9% to about HKD 35,100,000, up from HKD 12,700,000, driven by new long-term customer contracts and improved service levels[69] Financial Management and Governance - The company has engaged in discussions with financial institutions regarding the renewal of bank loans and obtaining new financing[17] - The financial statements have been prepared on a going concern basis, assuming the company can meet its financial obligations over the next twelve months[15] - The company adopted revised Hong Kong Financial Reporting Standards effective from January 1, 2025, which did not significantly impact the financial performance or position[19] - The company plans to adopt the new Hong Kong Financial Reporting Standard No. 18, which is expected to impact the presentation and disclosure of the consolidated statement of comprehensive income in future financial reports[22] - The company is currently evaluating the specific impact of the new financial reporting standard on its consolidated financial statements[21] - The independent auditor's report indicates that the financial statements fairly reflect the company's financial position as of December 31, 2025[95] - The audit committee has reviewed the financial statements and believes they are prepared in accordance with applicable accounting standards[97] Corporate Actions and Future Outlook - The company did not recommend any final dividend for the year, consistent with the previous year[7] - The company will hold its annual general meeting on May 14, 2026, and will suspend share transfer registration from May 11 to May 14, 2026[98] - The company will publish its annual report for the year on the Hong Kong Stock Exchange website and its own website[99] - The group plans to cautiously manage its core petrochemical and soybean trading businesses while optimizing resource allocation and investment strategies[70] - Future communications will likely provide insights into operational performance and growth strategies[100] Employee and Operational Costs - The group employed a total of 85 employees, with total employee costs, including director remuneration, amounting to approximately HKD 14,800,000[82] - The cost of inventory for 2025 was HKD 1,008,188, up from HKD 767,696 in 2024, reflecting increased operational costs[41] Risk Management - The group has no significant foreign exchange risk hedging measures in place, relying on monitoring and adjusting foreign currency cash flows[81]

Financial Performance - Total revenue for BaWang International (Group) Holding Limited reached approximately RMB 273.1 million, an increase of about 8.0% compared to RMB 253.0 million in the same period last year[2] - Operating profit decreased to approximately RMB 4.5 million, down about 41.2% from RMB 7.6 million in the previous year[2] - Net profit for the year was approximately RMB 3.9 million, a decline of about 40.7% compared to RMB 6.6 million in the same period last year[3] - Basic and diluted earnings per share were both RMB 0.1228, down from RMB 0.2073 in the previous year[4] - The company did not recommend the distribution of a final dividend based on the review of its operating performance[3] Revenue Breakdown - E-commerce channel revenue was approximately RMB 159.3 million, reflecting a growth of approximately 17.2% from RMB 135.9 million year-on-year[2] - The revenue for hair care products in 2025 was RMB 256,886 thousand, an increase from RMB 230,393 thousand in 2024, representing a growth of approximately 11.5%[14] - The total revenue for household and personal care products in 2025 was RMB 273,094 thousand, compared to RMB 252,952 thousand in 2024, indicating a growth of about 8%[14] - Revenue from external customers in China increased to RMB 269,996 thousand in 2025, up from RMB 250,143 thousand in 2024, representing a growth of approximately 7.4%[21] - Total revenue for the group reached RMB 273,094 thousand in 2025, compared to RMB 252,952 thousand in 2024, marking an increase of about 8%[21] Asset and Liability Management - Total assets minus current liabilities amounted to RMB 149.7 million, slightly down from RMB 151.1 million in the previous year[5] - Non-current assets increased to RMB 58.5 million from RMB 60.0 million year-on-year[5] - Cash and cash equivalents decreased to RMB 70.6 million from RMB 120.3 million in the previous year[5] - The company maintains a conservative financial management policy, with cash and bank balances of approximately RMB 115.6 million as of December 31, 2025, down from RMB 120.3 million in 2024[73] - Total assets as of December 31, 2025, are RMB 226.4 million, with a debt-to-asset ratio of 0%[74] Cost and Expenses - The cost of sales for 2025 is approximately RMB 134.2 million, an increase of about 8.1% from RMB 124.2 million in 2024, with the cost as a percentage of revenue slightly rising from 49.1% to 49.2%[46] - Gross profit increased to approximately RMB 138.8 million in 2025, up 7.8% from RMB 128.8 million in 2024, with a slight decrease in gross margin from 50.9% to 50.8%[47] - Selling and distribution expenses rose to approximately RMB 105.2 million, an increase of about 10.8% from RMB 94.9 million in 2024, with expenses as a percentage of revenue increasing from 37.5% to 38.5%[49][50] - Administrative expenses for 2025 are approximately RMB 32.1 million, up 9.4% from RMB 29.4 million in 2024, with expenses as a percentage of revenue increasing from 11.6% to 11.8%[51] Research and Development - Research and development costs recognized as expenses were RMB 14.1 million in 2025, up from RMB 13.0 million in 2024[26] - The company has established partnerships with several renowned universities and research institutions, enhancing its technical innovation capabilities and resulting in the publication of one journal article and the granting of one invention patent in the field of herbal medicine[67] - The R&D center spans 500 square meters and is equipped with advanced instruments such as HPLC and AAS, ensuring precise product testing and safety evaluations[68] Market Strategy and Brand Development - The company plans to enhance its brand products through continuous innovation in anti-hair loss technology, aiming to significantly improve market competitiveness[62] - The company intends to strengthen its brand positioning in professional hair care and expand its product offerings to attract younger consumers[63] - The company will optimize its product structure by phasing out underperforming product lines while promoting high-growth potential products[65] - The company has implemented a value chain-oriented business model to control sales and operating costs sustainably[34] - The company launched new product lines including Bawang toothpaste, Litao shower gel, and multi-effect nourishing series to meet diverse market demands[38] Operational Efficiency - The company has implemented automated production lines, optimizing internal management and production processes, which has effectively reduced costs and improved operational efficiency[69] - The company achieved zero industrial safety accidents throughout the year by enhancing safety training and emergency response capabilities for workers[70] Corporate Governance and Compliance - The company has complied with the corporate governance code as per the Hong Kong Stock Exchange rules as of December 31, 2025[82] - The audit and risk management committee has reviewed the group's annual performance for the year ended December 31, 2025, and recommended its adoption by the board[84] Future Outlook - The company plans to continue expanding its OEM business to enhance market share and influence in the industry[71] - Future strategies include forming management teams with rich experience in the household and personal care industry to restore sales growth and profitability[72] - The company will deepen insights into consumer demographics to drive product innovation and provide tailored solutions[66]

Financial Performance - Revenue increased by 23.0% to approximately RMB 2,241.9 million for the year ending December 31, 2025, compared to RMB 1,822.0 million in 2024[2] - Gross profit rose by 18.1% to approximately RMB 468.5 million, with a gross margin decrease of 0.9% to 20.9%[2] - Profit before tax increased by 32.5% to approximately RMB 216.0 million, up from RMB 163.0 million in the previous year[2] - Annual profit surged by 36.6% to approximately RMB 183.3 million, compared to RMB 134.2 million in 2024[2] - Earnings attributable to shareholders increased by 38.2% to approximately RMB 171.6 million, up from RMB 124.2 million in 2024[2] - Basic earnings per share rose by 37.1% to approximately RMB 0.48, compared to RMB 0.35 in the previous year[2] - The board proposed a final dividend of HKD 6.58 per share for the year ending December 31, 2025, up from HKD 5.56 in 2024[2] Assets and Liabilities - Non-current assets increased significantly to RMB 901.1 million from RMB 551.0 million in 2024, driven by investments in property and equipment[5] - Current assets rose to RMB 2,222.7 million, compared to RMB 1,592.5 million in 2024, with inventory increasing to RMB 1,047.1 million[5] - Total equity increased to RMB 1,543.5 million from RMB 1,300.6 million in 2024, reflecting strong financial performance and retained earnings[6] - Trade receivables increased to RMB 470,645 thousand in 2025 from RMB 287,210 thousand in 2024, reflecting a growth of 64%[36] - Trade payables increased to RMB 135,218 thousand in 2025 from RMB 62,266 thousand in 2024, representing a growth of 117%[38] - Bank borrowings rose from approximately RMB 599.3 million as of December 31, 2024, to approximately RMB 1,003.0 million as of December 31, 2025, driven by increased liquidity needs and specific loans for equipment at the Leizhou base[92] Revenue Breakdown - Revenue from mainland China (including Hong Kong and Taiwan) was RMB 1,783,273,000, up 23% from RMB 1,452,627,000 in the previous year[15] - Revenue from North America decreased to RMB 222,441,000, down 10% from RMB 246,456,000 in 2024[15] - The company reported sales of tantalum-niobium metal and its products at RMB 1,209,666,000, a significant increase from RMB 841,055,000 in 2024[21] - Revenue from tantalum-niobium metal and its products rose by approximately RMB 368.6 million or 43.8% to about RMB 1,209.7 million, driven by increased production and market demand[56] Costs and Expenses - The group's cost of goods sold rose to RMB 1,720,930 thousand in 2025, compared to RMB 1,381,761 thousand in 2024, reflecting increased production costs[28] - Financing costs increased to RMB 26,700 thousand in 2025 from RMB 24,421 thousand in 2024, driven by higher bank loan interest expenses[26] - Research and development expenses increased to RMB 92,808 thousand in 2025 from RMB 73,927 thousand in 2024, indicating a focus on innovation[28] - Administrative expenses rose from approximately RMB 183.8 million in 2024 to RMB 198.2 million in 2025, with R&D expenses increasing by RMB 18.9 million to RMB 92.8 million[67] Inventory and Receivables - Inventory increased from approximately RMB 744.5 million as of December 31, 2024, to approximately RMB 1,047.1 million as of December 31, 2025, driven by increased production scale[78] - The average inventory turnover days increased from 182.7 days in 2024 to 184.4 days in 2025, attributed to strategic inventory adjustments[81] - The provision for expected credit losses on trade receivables was approximately RMB 12.6 million in 2025, up from RMB 4.9 million in 2024[84] Corporate Governance - The board is committed to high standards of corporate governance and has adhered to applicable rules, with some deviations noted[119] - The chairman and CEO roles are currently held by the same individual, with plans to review this arrangement in the future[120] - The audit committee held two meetings during the review year, with all members present, and reviewed the financial statements and internal controls[123] Future Plans and Market Outlook - The group aims to optimize production capacity with a core goal of "quality improvement and efficiency enhancement," achieving significant results in process standardization and technical transformation[46] - The group plans to optimize its management structure and enhance decision-making capabilities by adding three vice presidents to lead key areas such as R&D innovation and production operations[109] - The group intends to deepen its engagement with high-end markets, particularly in AI and renewable energy sectors, to capture market opportunities[111] Employee and Talent Management - A total of 141 new talents were recruited in 2025, with nearly 60% holding a bachelor's degree or higher, strengthening the core technical and management team[44] - The group is committed to optimizing its compensation and benefits system to enhance employee satisfaction and motivation[113] Shareholder Information - The company will suspend the transfer of shares from May 21, 2026, to May 27, 2026, to determine eligibility for attending the annual general meeting and voting[114] - The final trading date for shares entitled to the final dividend is May 29, 2026, with the dividend expected to be paid on July 8, 2026[115]

Financial Performance - For the fiscal year ending December 31, 2025, the company reported revenue of HKD 204,949,000, a 74.3% increase from HKD 117,587,000 in 2024[2] - The gross profit for the fiscal year was HKD 42,394,000, representing a 208.4% increase from HKD 13,746,000 in 2024[12] - The company achieved a net profit attributable to shareholders of HKD 7,890,000, compared to a net loss of HKD 12,000,000 in the previous year[2] - Basic earnings per share for 2025 were HKD 0.77, a turnaround from a loss of HKD 1.18 per share in 2024[3] - The group reported a pre-tax profit of HKD 19,867,000 for the year ended December 31, 2025, compared to a pre-tax loss of HKD 12,000,000 for the year ended December 31, 2024[72] - The company reported a net profit of approximately HKD 7,890,000 for the fiscal year 2025, compared to a loss of HKD 12,000,000 in 2024, marking a significant turnaround[47] - Earnings per share for 2025 was HKD 0.77, a recovery from a loss of HKD 1.18 per share in 2024[47] Revenue Segments - The supply chain management services segment generated revenue of HKD 111,032,000, contributing approximately 54.2% to total revenue, a significant increase from HKD 9,520,000 in 2024[10] - The printing segment's revenue decreased by 13.1% to HKD 93,917,000 from HKD 108,067,000 in 2024, reflecting challenges in the market[9] - The logistics services segment generated revenue of HKD 107,009,000 in 2025, a substantial increase from HKD 9,520,000 in 2024[66] - For the year ended December 31, 2025, total external sales amounted to HKD 204,949,000, with the supply chain management segment contributing HKD 111,032,000 and the printing segment contributing HKD 93,917,000[72] Financial Position - As of December 31, 2025, the group's cash and cash equivalents amounted to approximately HKD 87,943,000, an increase from HKD 55,284,000 on December 31, 2024[22] - The current ratio as of December 31, 2025, was approximately 1.9, down from 4.3 on December 31, 2024, indicating a tighter liquidity position[23] - The debt-to-equity ratio as of December 31, 2025, was approximately 16.7%, compared to 7.1% on December 31, 2024, reflecting an increase in leverage[25] - The company’s total assets less current liabilities increased to HKD 155,390,000 in 2025 from HKD 117,573,000 in 2024, indicating strong financial health[62] Investments and Acquisitions - In 2025, the company acquired land in Zambia for logistics operations and entered into a service agreement with COSCO SHIPPING Africa to strengthen strategic cooperation[19] - The group has committed approximately HKD 16,333,000 in capital expenditures for the purchase of property, plant, and equipment as of December 31, 2025[29] - The group entered into a purchase agreement for land at a total price of USD 3,500,000 (approximately HKD 27.1 million) as part of its investment strategy[30] - The company issued HKD 20,100,000 of zero-coupon convertible bonds to DCQ Holdings Limited as part of financing for acquiring two leasehold lands in Zambia[83] Operational Developments - The group aims to solidify its supply chain management services as the core driver of revenue growth and profitability by 2026, focusing on strategic partnerships and operational capacity enhancement[20] - The group plans to expand its logistics and transportation networks across Africa, focusing on a logistics hub in Zambia to enhance its competitive advantage in the region[24] - The company established a new subsidiary in Zambia for supply chain management services, marking its expansion into new markets[70] Employee and Workforce - As of December 31, 2025, the total employee cost is approximately HKD 38.8 million, slightly up from HKD 38.5 million in 2024, with a total of 345 employees[37] - The company has reduced its workforce from 438 employees in 2024 to 345 employees in 2025[37] Financial Management and Strategy - The group has maintained a prudent financial management framework to ensure sufficient liquidity and manage cash flow risks effectively[26] - The group is actively seeking to diversify its capital structure by introducing strategic industry investors and exploring other financing options, including debt instruments[24] - The company has no plans for significant acquisitions or capital asset purchases as of the announcement date[35] - The company has no plans for significant investments or capital expenditures beyond what has been disclosed[35] Dividends and Shareholder Information - The company did not recommend any final dividend for the fiscal year 2025, consistent with 2024[4] - The group has not declared or proposed any dividends for the years ended December 31, 2025, and 2024[78] - The company maintains a public float of at least 25% of its issued share capital[56] Governance and Compliance - The audit committee has reviewed the financial statements for the fiscal year 2025, confirming compliance with applicable accounting principles and sufficient disclosures[58] - The financial statements for the year ended December 31, 2025, have been agreed upon by the auditors, although no assurance or verification conclusion was provided[85] - The company plans to publish its annual report containing all information required by the listing rules in a timely manner[87] Miscellaneous - The company has made significant progress in establishing a comprehensive logistics center, which is expected to enhance cross-border trade efficiency and reduce logistics costs[19] - The company has no significant contingent liabilities as of December 31, 2025, indicating a stable financial position[29] - The company has no assets pledged as of December 31, 2025, consistent with the previous year[36] - The company has not identified any significant events post-reporting period that could materially affect its operations or financial performance[45] - The board of directors has undergone a leadership change, with Mr. Wu stepping down as CEO while remaining as Chairman, and Mr. Zhu appointed as the new CEO[46][52] - The company expresses gratitude to business partners, shareholders, employees, and management for their continuous efforts and support[86]